Home / Recalls / Alvogen, Inc / D-0259-2026

D-0259-2026 Class II Ongoing

Recalled by Alvogen, Inc — Morristown, NJ

Recall Details

Product Type: Drugs
Report Date: January 21, 2026
Initiation Date: December 31, 2025
Termination Date: N/A
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity

Product Description

Levothyroxine Sodium Tablets, USP, Thyro-Tabs, 150mcg, 1000 Tablets, Rx only, Manufactured by: LLOYD, Inc., Shenandoah, IA, 51601 USA, Distributed by: Alvogen, Inc., Pine Brook, NJ 07058 USA, NDC: 47781-662-10.

Reason for Recall

Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.

Distribution Pattern

US Nationwide.

Code Information

Lot # MHA21825, Exp Date: December 31, 2027

Other recalls by Alvogen, Inc

D-0245-2025 Class I — Fentanyl Transdermal System CII, 25mcg/h, packaged in a pouch, further packaged (January 31, 2025)
D-0353-2023 Class II — Levothyroxine Sodium Tablets, USP 112 mcg, 90 tablets per bottle, Rx Only, Manuf (February 6, 2023)
D-0649-2021 Class II — Buprenorphine and Naloxone Sublingual Film 2mg/0.5mg, 30 pouches each containing (February 26, 2021)
D-1722-2019 Class II — Nitrofurantoin Monohydrate/Macrycrystals Capsules, 100 mg, 100-count bottle, Rx (July 24, 2019)
D-1723-2019 Class II — Macrobid Urinary Tract Anitbacterial, 100 mg, 100-count bottle, Rx Only, Mfg. b (July 24, 2019)
D-1277-2019 Class I — FENTANYL Transdermal System, 12 mcg/h, five (12 mcg/h) systems per carton, Rx on (April 19, 2019)
D-0939-2017 Class II — Clindamycin Injection USP; 300 mg/2 mL (150 mg/mL). 2 mL Single-dose ADD-VANTAGE (June 16, 2017)
D-0941-2017 Class II — Clindamycin Injection USP; 900 mg/6 mL (150 mg/mL). 6 mL Single-dose ADD-VANTAGE (June 16, 2017)
D-0940-2017 Class II — Clindamycin Injection USP; 600 mg/4 mL (150 mg/mL). 4 mL Single-dose ADD-VANTAGE (June 16, 2017)
D-0632-2017 Class III — Adalat CC (nifedipine) Extended-Release Tablets, 90 mg, 100-count bottles, Rx On (March 7, 2017)